During the telephone call and the first visit, patients will be able to ask any question. When the patient is properly informed and gives written informed consent the patient will be included for this study. Specific items such as duration of the study, the frequency of follow-up visits, and the voluntary nature of participation will be discussed prior to obtaining informed consent. Also, because of potential reproductive toxicity (no reports are known of developmental toxicity studies on Cr3+ compounds given orally), we will advice patients to take contraceptive precautions (33).